Search

Your search keyword '"bluebird bio, Inc. -- Product development"' showing total 8 results
Start Over Descriptor "bluebird bio, Inc. -- Product development" Publication Year Range This year
8 results on '"bluebird bio, Inc. -- Product development"'

1. Life Without Sickle Cell Beckons Boy Who Completed Gene Therapy

Author

Kolata, Gina and Holston, Kenny

Subjects
bluebird bio, Inc. -- Product development, Sickle cell anemia -- Care and treatment, Gene therapy -- Patient outcomes, Biotechnology industry -- Product development, General interest, News, opinion and commentary
Abstract

After 44 days, Kendric Cromer, 12, left the hospital. While his family feels fortunate that he was the first to receive a treatment, their difficult experiences hint at what others [...]

Published
2024

2. Vanguard of Sickle Cell-Free Patients Finds a Long, Hard Road

Author

Kolata, Gina and Holston, Kenny

Subjects
Sickle cell anemia -- Care and treatment, Gene therapy -- Patient outcomes -- Licensing, certification and accreditation, Biotechnology industry -- Product development, Pharmaceutical industry, bluebird bio, Inc. -- Product development, Vertex Pharmaceuticals Inc. -- Product development
Abstract

There was supposed to be a special party for Kendric Cromer, 12, last Wednesday, but it had to be postponed because he was too groggy to celebrate. It was meant [...]

Published
2024

3. Stem Cell Therapy Market to Register 11.2% CAGR by 2031 Amidst Expanding Pipeline of Clinical Trials

Subjects
bluebird bio, Inc. -- Product development, Stem cells -- Transplantation, Biotechnology industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-August 8, 2024-: Stem Cell Therapy Market to Register 11.2% CAGR by 2031 Amidst Expanding Pipeline of Clinical Trials (C)1994-2024 M2 COMMUNICATIONS RDATE:08082024 Stem Cell Therapy Market Size, Share, [...]

Published
2024

4. Sickle Cell Disease Pipeline Assessment 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | Bellicum Pharmaceuticals, Novartis, Novo Nordisk, more

Subjects
United States. Food and Drug Administration, bluebird bio, Inc. -- Product development, Vertex Pharmaceuticals Inc. -- Product development, Novartis AG -- Product development, Novo Nordisk A/S -- Product development, Sickle cell anemia, Business -- Research, Biotechnology industry -- Product development, Drug approval, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 20, 2024-: Sickle Cell Disease Pipeline Assessment 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | Bellicum Pharmaceuticals, Novartis, Novo Nordisk, more [...]

Published
2024

5. CAR-T Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)

Subjects
bluebird bio, Inc. -- Product development, Novartis Pharma AG -- Product development, Fate Therapeutics Inc. -- Product development, Business -- Research, Biotechnology industry -- Product development, Drug approval -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-May 7, 2024-: CAR-T Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated) (C)1994-2024 M2 COMMUNICATIONS RDATE:06052024 DelveInsight's, 'CAR-T Pipeline Insight 2024' report provides comprehensive insights about 120+ [...]

Published
2024

6. Car T Cell Therapy For Multiple Myeloma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CARsgen Therapeutics, Poseida Therapeutics, Juno

Subjects
bluebird bio, Inc. -- Product development, Cellectis S.A. -- Product development, T cells -- Reports, Biotechnology industry -- Product development, Drugs -- Product development, Multiple myeloma -- Drug therapy, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-January 12, 2024-: Car T Cell Therapy For Multiple Myeloma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CARsgen Therapeutics, Poseida Therapeutics, Juno [...]

Published
2024

7. Sickle Cell Disease Pipeline Report: FDA, EMA, and PMDA Approvals, Treatments, Clinical Trials, and Companies by DelveInsight | Bellicum Pharmaceuticals, Novartis, Novo Nordisk, Vertex Pharmaceuticals

Subjects
bluebird bio, Inc. -- Product development, Vertex Pharmaceuticals Inc. -- Product development, Novartis AG -- Product development, Novo Nordisk A/S -- Product development, Sickle cell anemia, Business -- Research, Drug approval, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-January 10, 2024-: Sickle Cell Disease Pipeline Report: FDA, EMA, and PMDA Approvals, Treatments, Clinical Trials, and Companies by DelveInsight | Bellicum Pharmaceuticals, Novartis, Novo Nordisk, Vertex Pharmaceuticals (C)1994-2024 [...]

Published
2024

8. Assessment of RNA Interference Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Companies by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio

Subjects
bluebird bio, Inc. -- Product development, Alnylam Pharmaceuticals Inc. -- Product development, Pfizer Inc. -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Business -- Research, Biotechnology industry -- Product development, RNA -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-January 9, 2024-: Assessment of RNA Interference Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Companies by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio (C)1994-2024 [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results